Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model
May 28, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, May 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced support for a new Phase 2 study designed to validate an innovative,...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
May 15, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company’s Karisma-Endoxifen clinical trial...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024 08:50 ET | Atossa Therapeutics, Inc.
Presented data from EVANGELINE study showing 100% disease control rate at 24-weeks Initiated study evaluating (Z)-endoxifen in combination with abemaciclib (VERZENIO®)Ended first quarter 2024 with...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Support of New Breast Cancer Screening Guidelines
May 07, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, May 07, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced its support of new guidelines released by the U.S. Preventive Services...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
April 29, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced an expanded research agreement with Weill Cornell Medicine to explore...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
April 15, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, April 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) and Quantum Leap Healthcare Collaborative™ today announced the initiation of a new...
Atossa_Therapeutics_logo-min.png
Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
April 11, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
April 09, 2024 11:59 ET | Atossa Therapeutics, Inc.
SEATTLE, April 09, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced promising safety and efficacy data from the Company’s Phase 2...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
April 01, 2024 16:00 ET | Atossa Therapeutics, Inc.
Fully enrolled two Phase 2 studies with data from both expected in the second half of 2024First patient dosed in new Phase 2 breast cancer prevention studyData from ongoing Phase 2 EVANGELINE study...
Atossa_Therapeutics_logo-min.png
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
March 19, 2024 08:30 ET | Atossa Therapeutics, Inc.
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that the pre-menopausal, Estrogen Receptor positive (ER+) / Human...